SIGLEC1 and cancer: These data indicate that GM3/TLR ligand-containing liposomes are suitable vectors for cancer vaccines, but that combined stimulation of TLR and inflammasome components via CD169-targeted GM3-containing liposomal delivery yields minor additive effects on the magnitude of the T cell response.